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METHOD OF STAMPING
SURFACE-ENHANCE RAMAN
SPECTROSCOPY FOR LABEL-FREE,
MULTIPLEXED, MOLECULAR SENSING
AND IMAGING
This application claims priority to U.S. Provisional Patent
Application Ser. No. 61/985,984, entitled "Method of
Stamping Surface-Enhance Raman Spectroscopy for Label-
Free, Multiplexed, Molecular Sensing and Imaging," filed
on Apr. 29, 2014, the entire contents of which are hereby
incorporated by reference.
This invention was made with government support under
Grant No. 50560 awarded by the National Science Founda-
tion, Grant No. G105289 awarded by NASA, Grant No.
G105128 awarded by GoMRI, National Science Foundation
(NSF) CAREER Award CBET-1151154, National Aeronau-
tics and Space Administration (NASA) Early Career Faculty
Grant NNX12AQ44G, and a grant from Gulf of Mexico
Research Initiative GoMRI-030. The United States Govern-
ment has certain rights in the invention.
BACKGROUND
Surface-enhanced Raman spectroscopy (SERS) is a spec-
troscopic technique, where Raman scattering is boosted
primarily by enhanced electric field due to localized surface
plasmon resonance (LSPR). With advances in nanofabrica-
tion techniques, SERS has attracted great attention for
label-free molecular sensing and imaging. However, the
practical use of SERS has often encountered a couple of
inherent issues. The first one is regarding a molecule transfer
step where target molecules need to be within the close
proximity of a SERS-active surface by either mixing with
nanoparticles or coating onto surface-bound nanostructures.
In other words, target molecules are required to be trans-
ferred from non-SERS-active surfaces to SERS-active ones,
normally in the solution phase, which can be problematic
due to issues such as surface affinity variability and uncer-
tainty, competitive adsorption among different molecules,
and contamination issues, causing irreproducible results and
erroneous or biased interpretations. More importantly, if the
spatial distribution of molecules on the surface prior to the
transfer step is of importance, such information is com-
pletely lost. Practically, solution-phase processes are rela-
tively more labor and time-consuming and require a "wet'
laboratory. Furthermore, SERS measurements are always
restricted to molecules adsorbed on metals such as Ag, An,
and Cu.
To address the aforementioned issues, many approaches
have been developed, and can be broadly classified into
chemical and physical means. Chemical approaches employ
functionalized surfaces to improve affinity and selectivity of
target molecules. For example, An nanoparticles were sur-
face-modified by cystamine and cysteine for detecting Per-
chlorate and trinitrotoluene, respectively. Physical
approaches, in contrast, attempt to bring the target molecules
to the SERS-active surface by physical manipulation. A
potential advantage of physical approach lies in that the
SERS enhancement depends solely on distance, rather than
surface affinity. For example, tip-enhanced Raman scattering
(TERS) technique introduces enhanced electromagnetic
field by bringing a nano-tip into the vicinity of target
molecules. Although TERS provides diffraction-unlimited
spatial resolution similar to that from atomic force micro-
scope, it is time-consuming for large area imaging. Li et al.
developed shell-isolated nanoparticle-enhanced Raman
N
spectroscopy (SHINERS), in which SERS-active nanopar-
ticles are coated over the surface with target molecules via
wet processes. Lee et al. demonstrated using gold nanorod-
loaded filter paper for SERS measurement by pre-wetting
5 and swabbing it on the surface to be probed.
SERS analyses have been performed to analyze biological
samples. For example, urine is an easily-accessible bodily
fluid that provides metabolic information, including the
renal status. Creatinine, a protein metabolite, is one of the
io major components of human urine besides urea. Since the
content of creatinine excreted into the urine is relatively
constant in the absence of renal disease, it is used as an
internal standard to normalize variations in other urine
analytes. Moreover, the detection of creatinine concentration
15 in the urine is important for renal clearance tests, which
monitor the filtration function of the kidney. Serum creati-
nine concentrations are routinely monitored as an indicator
of clinical renal function. In clinical diagnostics, serum and
urine creatinine concentrations are measured, and generally
20 a high creatinine level indicates kidney problems. For
example, normal levels of blood creatinine are approxi-
mately 0.6 to 1.2 mg/dl in adult males and 0.5 to 1.1 mg/dl
in adult females. In urine, however, creatinine is found to be
500-2000 mg over a 24-hour period. By simply dividing
25 500-2000 mg to the average urine volume of 1-2 L in an
adult male, the lower limit of urine creatinine concentration
is estimated to be —25 mg/dL.
Due to the importance of creatinine in clinical research, a
variety of analytical methods have been developed for
3o detecting creatinine in urine, including Jaffe reaction spec-
trophotometric method, enzymatic method, capillary zone
electrophoresis, high performance liquid chromatography
(HPLC), high performance thin-layer chromatography
(HPTLC), liquid chromatography tandem mass spectrom-
35 etry (LC-MS), gas chromatography mass spectrometry (GC-
MS), isotope dilution extractive electrospray ionization tan-
dem mass spectrometry (ESI-MS), Raman spectroscopy and
surface-enhanced Raman scattering (SERS). Compared to
traditional analytical methods, Raman and SERS methods
40 offer several advantages. They require no reagents or sepa-
ration, are non-invasive, are capable of qualitative and
quantitative measurements, and provide molecular structure
information. In particular, SERS is a highly-sensitive Raman
spectroscopic technique where Raman scattering is
45 enhanced primarily by near-field electromagnetic enhance-
ment due to localized surface plasmon resonance (LSPR).
Recent advances in the field of nanotechnology have paved
the way for the development of SERS based detection.
Most creatinine SERS analyses have thus far been per-
50 formed on metallic (e.g., Ag and Au) colloidal nanoparticles.
In general, Au-based SERS substrates are more stable,
nontoxic and biocompatible compared to Ag-based ones,
although they have inherently lower (i.e. 102-103 fold) SERS
effects than Ag-based substrates. By using gold colloids, the
55 potential of SERS for qualitative and quantitative creatinine
measurements was illustrated by W. R. Premasiri et al., and
the measurement of creatinine in human urine at concentra-
tions ranging from 2.56 to 115.2 mg/dl was reported by T. L.
Wang et al. Y. Wang et al. performed the detection of
60 creatinine water solution with concentrations ranging from
10-280 mg/dl by mixing with silver colloids. R. Stosch et al.
described the determination of creatinine in human serum at
physiologically relevant levels using silver colloids as SERS
substrates. In addition, nanostructured metal surfaces have
65 been employed for SERS measurements. Compared to
metallic colloids, a significant advantage of nanostructure
based approach is that SERS signals are more stable against
US 9,546,958 B2
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sample ionic strength. This is because the ionic strength can
affect the aggregation of metallic colloids and adversely
influence reproducibility. H. Wang et al. conducted quanti-
tative analysis of creatinine in the urine of healthy and
diabetic patients using Ag-coated parylene nanostructures as 5
the SERS substrate, and successfully detected as low as 6.1
mg/dl urine creatinine. K. W. Kho et al. analyzed urine
samples in a microfluidic device embedded with Au-coated
polystyrene nanosphere arrays as the SERS substrate.
Among existing reports, the lowest detectable concentration i0
was 0.1 µg/ml (-0.88 µM) in water, and 2.56 mg/dl in real
urine samples.
Although SERS has the potential for creatinine sensing,
both the limit of detection and reproducibility need further 15
improvement for practical application. As mentioned previ-
ously, colloidal SERS substrates suffer from sample ionic
strength dependent aggregation. Planar nanostructures, on
the other hand, may not provide low enough detection limit,
because the surface area within the source laser footprint is 20
small and the light-matter interaction is limited. This calls
for the development of robust, uniform, and reproducible
SERS substrates and reliable measurement techniques.
YIN► IL L11.a•
The present disclosure relates to label-free, multiplexed,
molecular sensing and large-area, high-resolution molecular
imaging on a flexible, non-plasmonic surface without solu-
tion-phase molecule transfer by stamping surface-enhanced 30
Raman spectroscopy. This disclosure represents a dry physi-
cal approach with decent sensitivity and imaging uniformity.
The present disclosure also relates to a novel reagent- and
separation-free method for measurement and analysis of
target molecules using stamping surface enhanced Raman 35
scattering (S-SERS) technique with nanoporous gold disk
(NPGD) plasmonic substrates, a further example of a label-
free, multiplexed molecular sensing and imaging technique.
The target molecules can be present in the environment or
deposited on a substrate for measurement. In preferred 40
examples, the present methods involve the measurement and
analysis of biolotical target molecules, such as creatinine
present in urine samples.
To produce volumetric SERS effects, nanoporous gold
disks (NPGDs) have been developed with large specific 45
areas for effective photothermal conversion and high-den-
sity plasmonic hot spots with an average SERS enhancement
factor (EF) exceeding 108, which provides a promising
platform to meet the needs. NPGDs are hierarchical with the
external disk shape and the internal three-dimensional (3D) 50
porous network. NPGDs feature large specific surface area,
high-density plasmonic hot-spots, and tunable plasmonics.
High-performance SERS substrates have been demon-
strated, providing efficient photothermal conversion and
light-gated molecular delivery and biomolecular detection in 55
microfluidics. The technique referred to as stamping SERS
(S-SERS) for label-free, multiplexed molecular sensing, and
large-area, high-resolution molecular imaging provides sev-
eral benefits such as reagent- and separation-free, low cost,
high sensitivity and reproducibility. 60
In certain applications, a substrate, such as a PDMS thin
film, is utilized as a carrier of target molecules. PDMS thin
film is preferable for its low cost, ease of fabrication,
mechanical flexibility, biocompatibility, relatively few
Raman peaks in the fingerprint region, and low auto-fluo- 65
rescence, although any suitable substrate may be used.
Target molecules are first deposited on the substrate, dried,
_►,
and then stamped onto a NPGD SERS substrate, followed by
SERS measurement from "sandwiched" molecules.
In preferred embodiments, a polydimethylsiloxane
(PDMS) thin film and nanoporous gold disk SERS substrate
play the roles of molecule carrier and Raman signal
enhancer, respectively. After stamping the SERS substrate
onto the PDMS film, SERS measurements can be directly
taken from the "sandwiched" target molecules. The perfor-
mance of S-SERS has been evaluated by the detection of
Rhodamine 6G (R6G), urea, and its mixture with acetamino-
phen (APAP), in physiologically relevant concentration
range, along with corresponding SERS spectroscopic maps.
S-SERS features simple sample preparation, low cost, and
high reproducibility, which could lead to SERS-based sens-
ing and imaging for point-of-care and forensics applications.
S-SERS has herein been utilized to measure creatinine
concentrations in samples of different levels of complexity.
The sensing reproducibility of this method using creatinine
dissolved in water has been examined. The detection limit,
robustness and multiplexing capability using pure creatinine
in water, mixtures of creatinine and urea in water, and
artificial urine spiked with creatinine have also been exam-
ined. Further, creatinine concentration measurements in
urines samples collected from a mouse model of nephritis
have been performed.
S-SERS is also useful in scenarios in which the target
molecules are present in the environment and are not depos-
ited by the user onto a carrier substrate. For example,
S-SERS can be used in the forensic analysis of crime scenes
or in any exploration in which molecular analysis would be
useful. In these applications, the NPGD substrate is stamped
directly onto the surface containing the target molecules and
then analyzed.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specifi-
cation and are included to further demonstrate certain
aspects of the present invention. The invention may be better
understood by reference to one or more of these drawings in
combination with the detailed description of specific
embodiments presented herein.
FIG. 1(a)-(h) shows schematics and corresponding
images of S-SERS and NPGDs, including: (a)-(c) sample
preparation; (d)-(f) visual images of sample preparation
procedures from (a)-(c); (g) SEM image of NPGDs; and (h)
SERS along the laser line from 100 µM R6G with average
spectrum (black solid line) and ±1 standard deviation (gray
shade).
FIGS. 2(a) and (b) shows before (`Normal") and after
stamping ("Stamped") SERS for: (a) R6G, and (b) Urea.
Insets show (a) variations of R6G peak intensity at 1366
cm-'; and (b) variations of Urea peak intensity at 1001 cm-'
vs. concentrations.
FIG. 3(a)-(f) shows SERS image of dried 100 µM R6G
(top) and 100 µM urea and 1 mM APAP mixture (bottom):
(a) bright filed image; (b) SERS map of peak intensity at
1366 cm-' for R6G; (c) spectra obtained at five different
positions shown in (b), with the 1366 cm-' peak marked by
(*); (d) SERS map of peak intensity at 1001 cm-' for urea;
(e) SERS map of peak intensity at 856 cm-' for APAP; and
(f) spectra obtained at five different positions shown in (d)
and (e), with major peaks for urea (*) and APAP O marked.
FIG. 4 shows SERS spectra obtained at varying concen-
trations of creatinine.
FIG. 5 shows SERS spectra obtained at varying concen-
trations of glucose.
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FIG. 6 (a)-(d) shows S-SERS configuration and NPGD
substrate in an example of the current method: (a) photo-
graph of the sandwich sample preparation scheme used in
the experiment for creatinine detection; (b) Schematic of
NPGD based SERS substrate; and (c)-(d) SEM images of 5
NPGD arrays at the magnification of (c) 100,000x and (d)
250,000x, with the scale bars in SEM images representing
200 mu.
FIG. 7 (a)-(b) shows data indicating reproducibility of
S-SERS for creatinine analysis: (a) SERS spectra of 100 µM 10
creatinine detected by S-SERS at ten different locations; and
(b) relative intensity variations of major peaks for the ten
locations.
FIG. 8 shows concentration-dependent SERS spectra of
creatinine measured by S-SERS at concentration ranging 15
from 100 nM to 100 µM. The insets indicate the variations
of creatinine peak intensity at 836 cm-' as a function of
creatinine concentration and the molecular structure of crea-
tinine. The error bars represent the standard deviation from
five measurements. 20
FIG. 9 (a)-(c) shows SERS spectra from creatinine and
urea water mixture: (a) Concentration-dependent SERS
spectra of 100 µM creatinine and 100 mM urea mixed at
different volume ratios; (b) a zoomed-in view of the dashed
window in (a), showing the intensity variation of creatinine; 25
and (c) a spectra of urea in water.
FIG. 10 shows concentration-dependent SERS spectra of
creatinine in artificial urine spiked with creatinine at con-
centrations of 10, 25, 50 and 200 µM. The inset shows
creatinine peak intensity at 836 cm-' versus concentration. 30
FIG. 11 (a)-(b) shows the performance of S-SERS on
urine from diseased mouse models: (a) concentration-de-
pendent SERS spectra of creatinine in urine samples col-
lected from a nephritic mouse model of anti-GBM disease;
and (b) the variations of creatinine peak intensity at 836 35
cm-' versus creatinine concentration, exhibiting good lin-
earity.
DETAILED DESCRIPTION
40
The present disclosure relates to the use of a stamping
surface enhanced Raman scattering (S-SERS) technique
with nanoporous gold disk (NPGD) plasmonic substrates to
produce a label-free, multiplexed molecular sensing and
imaging technique. The technique is a dry physical approach 45
with decent sensitivity and imaging uniformity. The tech-
nique utilizes nanoporous gold disks (NPGDs) with large
specific areas for effective photothermal conversion and
high-density plasmonic hot spots with an average SERS
enhancement factor (EF) exceeding 108. A NPGD SERS 50
substrate is stamped onto a surface containing one or more
target molecules for analysis, followed by SERS measure-
ment from "sandwiched" molecules. Alternatively, target
molecules are first deposited on a carrier substrate, which
can be a PDMS film, optionally dried, and then stamped onto 55
a NPGD SERS substrate for analysis. In preferred embodi-
ments, S-SERS is utilized to measure the concentration of
molecules such as glucose and creatinine.
NPG disk arrays can be fabricated directly on a thin
PDMS film. Using this as the SERS substrate, in principle 60
any surface can be stamped.
In preferred embodiments, the present technique takes
advantage of a substrate, such as PDMS, as a carrier
substrate for target molecules and NPGD with high-density
hot spots as the Raman signal enhancer, enabling SERS 65
measurement of sandwiched target molecules without solu-
tion-phase sample transfer onto the SERS-active surface.
T
R6G and urea detection with concentrations ranging from 10
nM to 100 µM has been demonstrated. Moreover, large-area,
high-resolution SERS maps of multiple molecules dried on
the PDMS surface has been demonstrated. By coupling with
high-throughput Raman imaging systems based on line-scan
or active-illumination, this technique can become a powerful
tool for forensics analysis. The capabilities of detecting and
imaging physiological concentrations of biological samples
could lead to new point-of-care applications.
The present technique also includes a reagent- and sepa-
ration-free method to determine creatinine concentrations in
urine based on stamping SERS and nanoporous gold disk
SERS substrates. The reproducibility has been demonstrated
by detecting 100 µM creatinine with relative intensity varia-
tions ranging from -12% to 12% across multiple samplings.
The detection of creatinine water solutions in the 100 nM to
100 µM range has been demonstrated with good linearity,
representing the first demonstration of sub-µM creatinine
sensing by any reagent- and separation-free technique.
Moreover, excellent concentration-dependent creatinine
sensing was successfully demonstrated in samples of
increasing complexity: urea water mixture, artificial urine,
and urine from nephritic mice. In particular, an unprec-
edented detection limit of -0.68 mg/dl has been achieved in
urine samples from nephritic mice. This is a significant
milestone because it approaches the performance of com-
mercial creatinine kits, however, without the need for
reagent and time-consuming assays. This method will pro-
vide a viable alternative for urine creatinine quantification
without the need for reagents or separation. Such technology
would provide invaluable information and utility in renal
function monitoring and disease diagnosis at both hospitals
and point-of-care scenarios.
Generally, preferred embodiments of the present method
of molecular sensing and imaging using stamping surface-
enhanced Raman spectroscopy (S-SERS) involve depositing
a surface-enhanced Raman spectroscopy (SERS) substrate
on top of at least one target molecule contained on a surface,
stamping the SERS substrate onto the surface to produce a
stamped SERS surface, and taking SERS measurements
directly from the target molecule, wherein the target mol-
ecule is positioned between the stamped SERS substrate and
the surface, and wherein the SERS measurements provide
sensing and imaging information about the target molecule.
In additional preferred embodiments, the target molecule is
first deposited on the surface, and the surface is a carrier
substrate.
Other preferred embodiments include an apparatus for
molecular sensing and imaging using stamping surface-
enhanced Raman spectroscopy (S-SERS) which comprises a
surface-enhanced Raman spectroscopy (SERS) substrate
stamped onto a surface containing a target molecule, and a
device for taking SERS measurements directly from the
target molecule, wherein the SERS measurements provide
sensing and imaging information about the target molecule.
The target molecule may be present on the surface or may
be deposited on the surface.
In preferred embodiments, a carrier substrate is used for
depositing the target molecules. The carrier substrate may be
polydimethylsiloxane (PDMS) film and the SERS substrate
comprises a nanoporous gold disk (NPGD). The target
molecule may also be dried after it is deposited on the carrier
substrate. The device used for taking SERS measurements
directly from the target molecule may be a Raman micros-
copy system. Examples of target molecules include Rhod-
amine 6G (R6G), urea, acetaminophen (APAP), glucose,
creatinine, or a combination thereof. In certain embodi-
US 9,546,958 B2
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ments, the target molecule is contained in a sample. The
sample may be a biological sample collected from a subject,
such as urine. The sensing and imaging information col-
lected using the method may be information confirming the
presence of the target molecule, or information regarding the
concentration of the target molecule.
EXAMPLE 1
S-SERS Scheme
FIG. 1(a-c) illustrate an example of the S-SERS scheme
with corresponding visual images shown in FIG. 1(d f).
First, 4µL of the prepared solution containing target mol-
ecules was dropped on the PDMS (Sylgard 184, Dow
Corning) thin film having a thickness of —125 µm and a
dimension of —1x1 cm2 (see FIGS. 1(a) and 1(d)), which
was prepared following standard protocols. The droplet was
then dried on the PDMS substrate, forming an ultra-thin film
of target molecules on the PDMS surface after solvent
evaporation in around 30 min (see FIGS. 1(b) and 1(e)).
Finally, a NPGD substrate was stamped onto the PDMS
surface with dried molecules, followed by focusing laser at
the PDMS surface to detect SERS signals of sandwiched
molecules (see FIGS. 1(c) and 1(f)). Monolayer NPGDs
densely distributed on Au-coated silicon substrates were
fabricated by the nanosphere lithography (NSL) technique
as previously described (M. Li, J. Lu, J. Qi, F. Zhao, J. Zeng,
J. C.-C. Yu, and W.-C. Shih, "Stamping surface-enhanced
Raman spectroscopy for label-free, multiplexed, molecular
sensing and imaging," Journal of Biomedical Optics 19(5),
050501 (2014), incorporated by reference herein). A scan-
ning electron microscopy (SEM) image was acquired to
show the structure of the NPGDs (see FIG. 1(g)) before
stamping.
A home-built line-scan Raman microscopy system with
785-nm excitation laser was employed. The laser power on
the sample was —28 mW over a 1 x133 µm2 line-shaped area,
and all the samples were measured with an integration time
of 10-20 sec for each scan step. To verify the performance
of the proposed technique, R6G with well-characterized
SERS spectrum was used. A 4µL droplet of 100 µM R6G
was dropped and dried on the PDMS surface, resulting in a
—1 mm spot. First, the measurement uniformity was exam-
ined by imaging a region around the mid-point between the
center and circumference of the dried spot, which appeared
visually uniform under bright-field microscopy. FIG. 1(h)
shows the statistics of a total of 350 SERS spectra across the
laser line where the solid line representing average spectrum
while the gray shade representing ±1 standard deviation. The
results suggest decent SERS uniformity across the sampled
region.
Next, it is shown that S-SERS can reveal apparently
invisible molecular coatings on PDMS. As shown in FIG.
2(a), R6G Raman spectrum from dried 100 µM solutions on
PDMS surface was measured and marked as "Normal". No
normal Raman spectrum was observed from any samples
with lower concentrations. NPGD substrate was then gently
stamped against the PDMS, after which the sample was
measured again and marked as "Stamped". Major Raman
peaks for R6G at 611, 771, 1185, 1317, 1366, 1515 and 1650
cm-' were observed. The 1366 cm-' peak intensity for 100
µM R6G exhibits a —10-fold enhancement after stamping.
EXAMPLE 2
S-SERS Applications
To examine the capability of the stamping protocol for
potential point-of-care and forensics applications, urea solu-
8
tions with different concentrations ranging from 10 nM to
100 µM were used to simulate urine tests. The same sample
preparation and measurement procedures aforementioned
were applied. As shown in FIG. 2(b), excellent intensity
5 enhancement can be seen after stamping, with the primary
Raman peak near 1001 cm-' corresponding to the symmetri-
cal C-N stretching vibration mode clearly observed. The
detection limit in the nanoMolar range is significantly lower
than most SERS results reported in the literature in the
10 milliMolar range, although direct comparison is not sug-
gested because the present technique employed dried
samples as opposed to continuous-flow measurements in
microfluidic configurations.
Conventional SERS measurements by transferring mol-
15 ecules of interest to SERS-active substrates can result in the
unavoidable loss of spatial distribution of molecules on the
original surface. To further demonstrate that the S-SERS
technique has the capability to obtain spatio-chemical infor-
mation from the PDMS surface, a 3-dimensional (x, y, X)
20 SERS map was recorded from dried 100 µM R6G samples.
The SERS map generated by peak intensity at 1366 cm-'
(FIG. 3(b)) showed an identical yet clearer boundary of
dried R6G droplet compared with the bright-field image
(FIG. 3(a)). Five different points inside the droplet were
25 chosen, and the corresponding spectra were shown in FIG.
3(c).
To demonstrate multiplexed sensing and imaging capa-
bilities, a 3-dimensional (x, y, X) SERS map was recorded
from dried mixture samples of 100 µM urea and 1 mM
30 acetaminophen (APAP). These concentrations are relevant
for successful detection in urine. After stamping, the dry
mark could not be found using bright-field microscopy
because both molecules are colorless; however, SERS maps
successfully provided the spatial distribution information of
35 both. As shown in the bottom row of FIG. 3, the SERS map
generated by peak intensity at 1001 cm-' for urea (FIG.
3(d)) showed a similar overall boundary of dried droplet to
the one generated by peak intensity at 856 cm-' for APAP
(FIG. 3(e)), but different spatial distribution. As shown in
40 FIG. 30, spectra from five different positions were pre-
sented. For example, the peak intensity ratio of urea's major
peak at 1001 cm-' to that of APAP at 856 cm-' is 2.45 at
position 2 (P2), while the ratio is 0.67 at position 4 (P4). The
results suggest that the two different molecules did not
45 uniformly distribute on the PDMS surface during drying,
likely due to differences in density, solubility, concentration,
and amity to the PDMS surface, etc. The mixture data were
collected from the circumference to emphasize the detection
of the drying edge, where the well-known "coffee ring"
50 effect caused more molecular accumulation.
Physiologically important analytes such as glucose and
creatinine can be measured by the Stamp-SERS protocol at
physiologically relevant concentrations. See FIGS. 4 and 5
for the SERS spectra obtained for different concentrations of
55 creatinine and glucose.
EXAMPLE 3
Detection of Creatinine
60
Creatinine (C4255, anhydrous, >_98%) and urea (U5378,
powder) were purchased from Sigma-Aldrich. Sample solu-
tions of individual molecules were prepared by dissolving
the powders in deionized (DI) water, and then diluted to
65 various concentrations. Sodium chloride, potassium, and
sodium phosphate (monobasic, monohydrate) were pur-
chased from MacronTM Chemicals. Artificial urine was pre-
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pared using 24.2 g urea, 10 g sodium chloride, 6.0 g
potassium, and 6.4 g sodium phosphate (monobasic, mono-
hydrate) dissolved in 1 L DI water. Polydimethylsiloxane
(PDMS, Sylgard 184, Dow Corning) was prepared by thor-
oughly mixing base and curing agent at a weight ratio of 5
10:1, and then poured over the bottom surface of a petri dish,
degassed, and finally cured on a hot plate at 70° C. for 1 h.
In these experiments, large-area, uniform, and reproduc-
ible NPGD arrays patterned on Au-coated silicon substrate
were utilized as SERS substrates. NPGDs were fabricated io
with Ag An alloy (Ag,,Au30, atomic ratio 70:30) using a
process similar to nanosphere lithography (NSL). The
detailed procedure has been previously reported (M. Li, J.
Lu, J. Qi, F. Zhao, J. Zeng, J. C.-C. Yu, and W.-C. Shih,
"Stamping surface-enhanced Raman spectroscopy for label- 15
free, multiplexed, molecular sensing and imaging," Journal
of Biomedical Optics 19(5), 050501 (2014), incorporated by
reference herein). Briefly, the fabrication process started
with depositing layers (20 nm Cr/200 nm Au) by evapora-
tion on a clean silicon wafer, and then a 120 mu-thickAg/Au 20
alloy layer by sputtering. After that, a monolayer of 460
ran-diameter polystyrene (PS) beads serving as masks was
deposited onto the surface. A two-step plasma treatment was
performed subsequently: oxygen and argon treatment to
shrink PS beads and etch away the unprotected portion of the 25
alloy film, respectively. Finally, NPGDs were formed by
removing PS residues by sonication in chloroform, and
dealloying in concentrated nitric acid.
SERS measurements were performed using a home-built
line-scan system with a 785-nm continuous-wave (CW) 30
Titanium: Sapphire laser (3900S, Spectra-Physics). The exci-
tation laser was shaped into a 1 x133 µm2 line at the sample
plane. The SERS spectra were recorded by a spectrograph-
charge coupled device (CCD) system (LS-785, P1Acton)
controlled by Winspec software (P1Acton), and post-pro- 35
cessed using Matlab (Mathworks). Spectroscopic back-
grounds were approximated by a 5th order polynomial and
removed. Image curvature due to off-axis light incidence and
the large-area CCD detector was corrected by a software
technique. 40
FIG. 6(a) shows the sample configuration used in the
experiment. First, a 1µL droplet of the prepared solution
containing the target molecules (i.e. creatinine) was first
pipetted onto a PDMS thin film (-1 x  cm2, -100 µm thick)
laid flat on a glass coverslip. The droplet was then dried on 45
the PDMS substrate, forming a film of target molecules after
solvent evaporation. After that, a NPGD substrate (-0.5x0.5
cm2) was stamped onto the PDMS surface bearing dried
target molecules. Finally, the laser was focused at the PDMS
surface to detect SERS signals from the sandwiched target 50
molecules. Compared to directly drying the droplet onto the
NPGD substrate, where target molecules are permanently
chemically bound to the SERS substrate, the related issues
like competitive adsorption among different molecules, sur-
face and molecule affinity variability and uncertainty are 55
reduced to some extent by the S-SERS technique. FIG. 6(b)
shows the schematic of the NPGD arrays serving as Raman
signal enhancers. Scanning electron microscope (SEM)
images recorded are shown in FIGS. 6(c) and 6(d) to
illustrate the structure and morphology of the NPGD arrays. 60
The fabricated NPGDs have average diameter, thickness,
and pore size of -300, 75, and 14 mu, respectively.
To demonstrate reproducibility of S-SERS for creatinine
analysis, a 1µL droplet of 100 µM creatinine was pipetted
and dried on the PDMS surface, resulting in a spot with a 65
diameter of -0.5 mm. NPGD substrate was then gently
stamped against the PDMS film with creatinine until inti-
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mate contact was formed, after which the sample was
measured from the coverslip side. SERS spectra were
acquired with 30 mW laser power and 10 sec acquisition
time each. The laser power density was estimated to be 0.25
mW per µm2. FIG. 7 shows highly-reproducible SERS
spectra from ten randomly chosen locations 100 µm away
from the circumference of the drying mark of creatinine
droplet, where dominant SERS peaks corresponding to
creatinine, i.e. 573, 602, 671, 836, 900, 1245, 1417, 1645,
and 1707 cm-' were identified. As shown in FIG. 7(b), the
relative intensity variations of the major creatinine peaks
were calculated to be within -12% to 12% of the average
intensity, when repeatedly assayed from different locations.
Similar reproducibility has been obtained from previous
NPGD substrates.
In order to further assess the sensing capability of S-SERS
for creatinine analysis, measurements were performed for
creatinine water solutions of different concentrations rang-
ing from 100 nM to 100 µM. The measurements for each
creatinine concentration were performed five times with 30
mW laser power and 20 sec CCD integration time. The
resulting averaged SERS spectra are shown in FIG. 8, where
major creatinine Raman peaks were identified in all spectra,
and the peak intensity increased with increasing creatinine
concentration. The Raman spectrum of 10 µM creatinine
before stamping is also presented at the bottom for com-
parison (black line), where creatinine peaks can hardly be
identified. In contrast, S-SERS provides excellent creatinine
spectrum at concentrations as low as 100 nM. The limit of
detection of creatinine in water is estimated to be 13.2 nM
based on the signal to noise ratio (22.7) at 100 nM. The inset
shows a good linear relationship of intensity variations of
the 836 cm-' peak as a function of creatinine concentration
within the range of 100 nM to 100 µM.
Since urea is a dominant chemical constituent in urine
samples, a reagent- and separation-free technique needs to
provide selectivity based on intrinsic molecular fingerprints.
To demonstrate the multiplexed sensing capabilities of
S-SERS, measurements were performed on samples pre-
pared by mixing 100 µM creatinine and 100 mM urea
solutions at five different volume ratios, namely 10:1, 10:2,
10:3, 10:4, and 10:5. The resultant concentration of creati-
nine ranges from 66.7 to 90.9 µM, and urea ranges from 9
to 33 mM. Both concentration ranges correspond to physi-
ological concentrations in urine, and are relevant for prac-
tical urine analysis. Five measurements were conducted for
each volume ratio to obtain the averaged spectra and stan-
dard deviation. The averaged SERS spectra of creatinine and
urea mixture at five different ratios are shown in FIG. 9.
Correlation between peak intensity and concentration can be
identified for both creatinine (i.e. at 602, 671, 836 and 900
cm-') and urea (i.e. at 1003 cm-'). The results show that
concentration-dependent creatinine SERS can be obtained
even in the co-presence of -100x higher concentration of
urea. In addition, the creatinine peak intensity from pure
creatinine and was compared to the mixture of creatinine
and urea (i.e., FIG. 8 versus FIG. 9). The intensity at -836
cm-' from the mixture (FIG. 9) was about 17% lower than
that from the pure sample (FIG. 8). This could be attributed
to preferential surface crowding: urea, besides being present
at higher concentration, may occupy more surface area on
the PDMS film than creatinine. In addition, high concentra-
tion urea would change the refractive index, thus affecting
laser spot size and collection efficiency.
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EXAMPLE 4
Detection of Creatinine in Urine
In order to test the capability of S-SERS for quantitative
analysis of creatinine in a more complex mixture, creatinine
was added to artificial urine with resultant concentrations of
10, 25, 50 and 200 µM. Each sample was measured five
times, and the averaged SERS spectra are shown in FIG. 10.
From spot to spot, the urea signature peak at 1003 cm-'
shows an intensity variation of less than 5%, which further
indicates the high reproducibility of S-SERS. Moreover,
with the increase of creatinine concentration, the major
peaks for creatinine (i.e. 602, 671, 836 and 900 cm-')
increased in intensity. The inset indicates the variations of
creatinine peak intensity at 836 cm-' as a function of
creatinine concentration, and a good linearly relationship is
observed. The creatinine peak intensity at the same concen-
tration (i.e. 10 µM) from pure creatinine was also compared
to creatinine in artificial urine (i.e., FIG. 8 versus FIG. 10).
The intensity at —836 cm-' from the doped artificial urine
sample (FIG. 10) was about 35% lower than that from the
pure creatinine sample (FIG. 8). This is likely primarily due
to preferential surface crowding by other molecules in the
mixture.
S-SERS was further employed to measure creatinine in
urine samples collected from nephritic mice with anti-GBM
disease induced as described before. The "ground truth"
creatinine concentrations in these samples from different
mice were determined using a commercial colorimetric
assay kit based on a coupled enzyme reactions (#80350,
Crystal Chem, Inc.) with a detection limit —0.15 mg/dl
according to product specifications. In this assay, the crea-
tinine is broken down to creatine, and then converted to
sarcosine. The sarcosine is oxidized to hydrogen peroxides,
which react with peroxidase, and can be quantified by
measuring light absorption at 550 mu. The entire assay from
warming up reagents to room temperature to calculating
creatinine concentration would take —1 hour at the very
least.
FIG. 11(a) shows averaged SERS spectra of the different
mouse urine samples with creatinine concentrations at 2.08,
6.16, 12.55, 22.55, and 30.30 mg/dl. 1 mg/dL corresponds to
88.4 µM for creatinine in water. The major SERS peaks of
creatinine at 602, 671, and 836 cm-' can once again be
identified in the mouse urine samples. A good linear rela-
tionship is observed by plotting the peak intensity at 836
cm-' versus creatinine concentrations as shown in FIG.
11(b). Although the lowest concentration in this experiment
was 2.08 mg/dl, the limit of detection is estimated to be 0.68
mg/dl based on the signal to noise ratio (9.14) at 2.08 mg/dl.
When one compares the creatinine peak intensity at —836
cm-' from real urine to that of creatinine water solution at
the same concentration (i.e. FIG. 8), the intensity from real
urine is about 6-fold lower than that from the creatinine
water solution. Besides preferential surface crowding from
other urine analytes and proteins, this difference may relate
to the non-transparent, dark yellow color of the urine, which
might have caused light attenuation and local refractive
index changes. The results show that this new approach
provides a reagent- and separation-free method for creati-
nine concentration measurements in real urine samples. It is
remarkable that S-SERS is still able to capture the creati-
nine-specific signature despite the co-existence of >70 pro-
teins in these nephritic urine samples. This is attributed to
the intrinsic molecular fingerprinting capability of Raman
and SERS spectroscopy.
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The invention claimed is:
1. A method of molecular sensing and imaging using
stamping surface-enhanced Raman spectroscopy (S-SERS),
the method comprising:
5 (a) depositing a surface-enhanced Raman spectroscopy
(SERS) substrate on top of a surface comprising at least
one target molecule;
(b) stamping the SERS substrate onto the surface to
produce a stamped SERS surface; and
l0 (c) taking SERS measurements directly from the at least
one target molecule, wherein the at least one target
molecule is positioned between the stamped SERS
substrate and the surface, and wherein the SERS mea-
15 surements provide sensing and imaging information
about the target molecule.
2. The method of claim 1, further comprising the step of
depositing at least one target molecule on the surface before
depositing the surface-enhanced Raman spectroscopy
20 (SERS) substrate, wherein the surface is a carrier substrate.
3. The method of claim 2, wherein the carrier substrate is
a polydimethy siloxane (PDMS) film.
4. The method of claim 2, wherein the step of depositing
at least one target molecule on the surface further comprises
25 drying the at least one target molecule.
5. The method of claim 2, wherein the target molecule is
contained in a sample.
6. The method of claim 5, wherein the sample is a
biological sample collected from a subject.
30 7. The method of claim 1, wherein the SERS substrate
comprises a nanoporous gold disk (NPGD).
8. The method of claim 1, wherein the target molecule is
Rhodamine 6G (R6G), urea, acetaminophen (APAP), glu-
35 cose, creatinine, or a combination thereof.
9. The method of claim 1, wherein the sensing and
imaging information is information confirming the presence
of the target molecule.
10. The method of claim 1, wherein the sensing and
40 imaging information is information regarding the concen-
tration of the target molecule.
11. The method of claim 1, wherein the step of taking
SERS measurements directly from the at least one target
molecule is performed by a Raman microscopy system.
45 12. An apparatus for molecular sensing and imaging using
stamping surface-enhanced Raman spectroscopy (S-SERS)
comprising:
a surface-enhanced Raman spectroscopy (SERS) sub-
strate stamped onto a surface on top of at least one
50 target molecule; and
a device for taking SERS measurements directly from the
at least one target molecule, wherein the SERS mea-
surements provide sensing and imaging information
about the target molecule.
55 13. The apparatus of claim 12, wherein the surface is a
carrier substrate, and wherein the at least one target mol-
ecule is deposited on the carrier substrate.
14. The apparatus of claim 13, wherein the carrier sub-
strate is polydimethylsiloxane (PDMS) film.
60 15. The apparatus of claim 13, wherein the target mol-
ecule is contained in a sample.
16. The apparatus of claim 15, wherein the sample is a
biological sample collected from a subject.
17. The apparatus of claim 12, wherein the SERS sub-
65 strate comprises a nanoporous gold disk (NPGD).
18. The apparatus of claim 12, wherein the device for
taking SERS measurements is a Raman microscopy system.
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19. The apparatus of claim 12, wherein the target mol-
ecule is Rhodamine 6G (R6G), urea, acetaminophen
(APAP), glucose, creatinine, or a combination thereof.
20. The apparatus of claim 12, wherein the sensing and
imaging information is information confirming the presence s
of the target molecule.
21. The apparatus of claim 12, wherein the sensing and
imaging information is information regarding the concen-
tration of the target molecule.
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